January 10, 2015
Quick start into the new year
Dear reader
The editors at startupticker are currently working hard on the Swiss Venture Capital Report 2014, which will appear in late January. But although we are still analysing the past year, we have already reported on the first financing round highlight of 2015. Genkyotex, a biotech company based in Geneva, has generated CHF20 million and is considering an IPO later this year.
Zurich biotech company Redbiotec has completed a partial exit. It has sold its spin-off Redvax to US group Pfizer. Redbiotec will keep its core technology and IP for all further applications.
It’s not only start-ups that develop dynamically but also supporters. A very good example is Innocampus in Biel, which is led by serial entrepreneur Felix Kunz. Although the innovation park is still in the start phase, Kunz reveals in this interview why it is already an attractive location for innovative companies, and where its focus and strengths lie. We are also pleased to welcome Innocampus as another supporter of startupticker.
In recent days, we have reported on a number of other supporters. The BlueLion in Zurich applies its start-up methodology to corporate innovation projects, and UBS, the largest Swiss bank, is the first to enter into a partnership with BlueLion. The technology parks and incubators in Basel have developed steadily over recent months, and ETH Zurich’s funding programme for company founders has proved its worth. There is also support outside Switzerland in the booming start-up hub of Boston through swissnex Boston.
There will be news of startupticker itself at both startupticker brunches, in Zurich on 27 January and in Lausanne on 29 January. You can now register directly on our site for both events and pre-order the Swiss Venture Capital Report 2014. If you provide us with your postal address, we will send you a free print copy of the report.
Have a relaxing weekend.
Stefan Kyora
Managing Editor, startupticker.ch
News
The new Swiss Venture Capital Report was published on 26 January. It analyses 304 financing rounds closed in 2020 and includes further article such as an interview with Michael Hengartner, President of the ETH Board, and a list of Swiss "soonicorns". 
